{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:54:58Z","timestamp":1785354898039,"version":"3.55.0"},"reference-count":17,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,11,25]],"date-time":"2015-11-25T00:00:00Z","timestamp":1448409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Neurosearch A\/S, Ballerup, DenmarkNeurosearch A\/S, Ballerup, Denmark"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>Pridopidine, a new oral drug for treatment of patients with motor symptoms associated with Huntington's Disease (HD) is currently under development. In steady\u2010state conditions, pridopidine elimination is mediated primarily through renal excretion. This study evaluated single dose and steady\u2010state pharmacokinetics (PK) of a daily dose of pridopidine in subjects with mild and moderate renal impairment and matched healthy subjects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Subjects with mild renal impairment (<jats:italic>n<\/jats:italic>\u00a0=\u00a012), moderate impairment (<jats:italic>n<\/jats:italic>\u00a0=\u00a012), or their matched healthy controls (<jats:italic>n<\/jats:italic>\u00a0=\u00a025) participated in this study. Subjects received a single dose of pridopidine (45\u00a0mg) on day 1 and a multiple dose cycle of 45\u00a0mg once daily on days 5\u201318. Blood and urine samples were collected on days 1 and 18 for PK analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Mild renal impairment did not affect the PK of pridopidine whilst an increase in exposure was seen in subjects with moderate renal impairment. Subjects with moderate impairment showed reduced plasma clearance (by 44%) and had 68% higher AUC (90% CI 1.22, 2.30) and 26% higher <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> (90% CI 1.02, 1.56) values than those with normal renal function at steady\u2010state. Pridopidine was safe and well tolerated in healthy subjects and in subjects with mild and moderate renal impairment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Mild renal impairment has no impact on exposure to pridopidine while moderately impaired renal function resulted in higher pridopidine concentrations.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.12792","type":"journal-article","created":{"date-parts":[[2015,9,25]],"date-time":"2015-09-25T17:39:01Z","timestamp":1443202741000},"page":"246-255","source":"Crossref","is-referenced-by-count":5,"title":["The effect of mild and moderate renal impairment on the pharmacokinetics of pridopidine, a new drug for Huntington's disease"],"prefix":"10.1111","volume":"81","author":[{"given":"L.","family":"Rabinovich\u2010Guilatt","sequence":"first","affiliation":[{"name":"Phase\u20101 and Clinical Pharmacology, Clinical Development and Medical, Global R&amp;D Teva Pharmaceuticals  Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. E.","family":"Siegler","sequence":"additional","affiliation":[{"name":"CRS Clinical Research Services Mannheim GmbH  Gruenstadt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Schultz","sequence":"additional","affiliation":[{"name":"CRS Clinical Research Services Mannheim GmbH  Gruenstadt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Halabi","sequence":"additional","affiliation":[{"name":"CRS Clinical Research Services Kiel GmbH  Kiel Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rembratt","sequence":"additional","affiliation":[{"name":"Formerly NeuroSearch A\/S, Denmark and currently Novo Nordisk A\/S  Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Spiegelstein","sequence":"additional","affiliation":[{"name":"Phase\u20101 and Clinical Pharmacology, Clinical Development and Medical, Global R&amp;D Teva Pharmaceuticals  Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,11,25]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000086373.32347.16"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750\u20101172\u20105\u201040"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2010.07.023"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70233-2"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182886965"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25362"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-012-0100-2"},{"key":"e_1_2_9_9_1","unstructured":"\u00d8sterbergO SundgreenC IvkovicJ MugliaP PrangA DarpoB.A single center randomized placebo\u2010controlled double\u2010blind study to evaluate the safety tolerability and pharmacokinetics of multiple\u2010ascending doses of pridopidine in healthy volunteers. Presented at The 7th European Huntington's Disease Network Plenary Meeting.Stockholm Sweden14\u201316September 2012."},{"key":"e_1_2_9_10_1","unstructured":"Rabinovich\u2010GuilattL SpiegelsteinO WickenbergA BassanM.A drug\u2010drug interaction study of pridopidine a new drug for treatment of Huntington's disease and metoprolol a cytochrome P450 2D6 substrate. Presented at the World Congress on Huntington's Disease Rio de Janeiro Brazil September15\u201318 2013."},{"key":"e_1_2_9_11_1","unstructured":"WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI.Ethical Principles for Medical Research Involving Human Subjects. Available athttp:\/\/www.wma.net\/en\/30publications\/10policies\/b3\/17c.pdf(last accessed 27 October 2015)."},{"key":"e_1_2_9_12_1","unstructured":"Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance.http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/ucm073122.pdf(last accessed 27 October 2015)."},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2006.077180"},{"key":"e_1_2_9_14_1","volume-title":"Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function \u2010 Study Design, Data Analysis, and Impact on Dosing and Labeling","author":"US Food and Drug Administration","year":"1998"},{"key":"e_1_2_9_15_1","unstructured":"Guidance for Industry Pharmacokinetics in Patients with Impaired Renal Function Study Design Data Analysis and Impact on Dosing and Labeling (March2010). Available athttp:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM204959.pdf(last accessed 27 October 2015)."},{"key":"e_1_2_9_16_1","unstructured":"European Medicines Agency.Note for Guidance on the Evaluation of the Pharmacokinetics of Medicinal Products in Patients with Impaired Renal Function (CHMP\/EWP\/225\/02). London UK.2004. Available athttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003123.pdf(last accessed 27 October 2015)."},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1248-z"},{"key":"e_1_2_9_18_1","first-page":"571","article-title":"Design of the dose\u2010range finding (DRF), randomized, double\u2010blind, placebo\u2010controlled study, evaluating the safety and efficacy of pridopidine for symptomatic treatment in patients with Huntington's disease [abstract]","volume":"29","author":"Landwehrmeyer GB","year":"2014","journal-title":"Mov Disord"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.12792","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.12792","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.12792","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.12792","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T09:56:32Z","timestamp":1696326992000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.12792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,25]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.1111\/bcp.12792"],"URL":"https:\/\/doi.org\/10.1111\/bcp.12792","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,25]]}}}